United States - English - NLM (National Library of Medicine)

mutual pharmaceutical company, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 400 mg - carefully consider the potential benefits and risks of tolmetin sodium and other treatment options before deciding to use tolmetin sodium. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). tolmetin sodium is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium is indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium is also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration ). tolmetin sodium is contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin sodium should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, an

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 400 mg - carefully consider the potential benefits and risks of tolmetin sodium capsules, usp and other treatment options before deciding to use tolmetin sodium capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium capsules are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 600 mg - carefully consider the potential benefits and risks of tolmetin sodium tablets, usp and other treatment options before deciding to use tolmetin sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium tablets are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium tablets are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium tablets have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium tablets are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after t

United States - English - NLM (National Library of Medicine)

stat rx usa llc - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin sodium 600 mg - carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin is contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaph

Israel - English - Ministry of Health

gsk consumer healthcare, israel ltd - dimetindene maleate; phenylephrine - nasal solution - dimetindene maleate 0.025 %w/v; phenylephrine 0.25 %w/v - dimetindene - dimetindene - symptomatic treatment of common cold, nasal congestio, acute rhinitis, seasonal (hay fever) and non seasonal allergic rhinitis, acute sinusitis. adjunctive therapy in case of acute otitis media.

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - carefully consider the potential benefits and risks of tolmetin sodium tablets, usp and other treatment options before deciding to use tolmetin sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium tablets are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium tablets are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium tablets have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium tablets are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type re

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - carefully consider the potential benefits and risks of tolmetin sodium capsules, usp and other treatment options before deciding to use tolmetin sodium capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium capsules are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions

Israel - English - Ministry of Health

gsk consumer healthcare, israel ltd - dimetindene maleate - drops - dimetindene maleate 1 mg/ml - dimetindene - dimetindene - antipruritic, antihistaminic and antiallergic.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - trametinib dimethyl sulfoxide, quantity: 2.254 mg (equivalent: trametinib, qty 2 mg) - tablet, film coated - excipient ingredients: mannitol; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; sodium lauryl sulfate; hypromellose; titanium dioxide; polysorbate 80; iron oxide red; macrogol 400 - unresectable or metastatic melanoma,mekinist in combination with dabrafenib is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma.,mekinist as a monotherapy is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is intolerance to braf inhibitors or braf inhibitors cannot be used.,mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy (see section 5.1 clinical trials).,adjuvant treatment of melanoma,mekinist in combination with dabrafenib is indicated for the adjuvant treatment of patients with melanoma with a braf v600 mutation and involvement of the lymph node(s), following complete resection.,anaplastic thyroid cancer (atc),mekinist in combination with dabrafenib is indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with a braf v600 mutation and with no satisfactory locoregional treatment options.,non-small cell lung cancer (nsclc),mekinist in combination with dabrafenib is indicated for the treatment of patients with advanced non-small cell lung cancer (nsclc) with a braf v600 mutation.,low-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy (see section 5.1 clinical studies).,high-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with high-grade glioma (hgg) with a braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options (see section 5.1 clinical studies). .

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - trametinib dimethyl sulfoxide, quantity: 0.5635 mg (equivalent: trametinib, qty 0.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; iron oxide yellow; macrogol 400 - unresectable or metastatic melanoma,mekinist in combination with dabrafenib is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma.,mekinist as a monotherapy is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is intolerance to braf inhibitors or braf inhibitors cannot be used.,mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy (see section 5.1 clinical trials).,adjuvant treatment of melanoma,mekinist in combination with dabrafenib is indicated for the adjuvant treatment of patients with melanoma with a braf v600 mutation and involvement of the lymph node(s), following complete resection.,anaplastic thyroid cancer (atc),mekinist in combination with dabrafenib is indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with a braf v600 mutation and with no satisfactory locoregional treatment options.,non-small cell lung cancer (nsclc),mekinist in combination with dabrafenib is indicated for the treatment of patients with advanced non-small cell lung cancer (nsclc) with a braf v600 mutation.,low-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy (see section 5.1 clinical studies).,high-grade glioma,mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with high-grade glioma (hgg) with a braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options (see section 5.1 clinical studies).